Innate Pharma S.A. IPHA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.52% | -9.27% | -4.29% | -16.39% | -36.03% |
| Total Depreciation and Amortization | -11.39% | -18.89% | -27.54% | -34.59% | -39.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.19% | 15.49% | 313.26% | 502.00% | 1,259.88% |
| Change in Net Operating Assets | 242.87% | -122.60% | -126.84% | -123.75% | -113.49% |
| Cash from Operations | -10.93% | -116.26% | -693.31% | -284.24% | -129.31% |
| Capital Expenditure | -11.20% | 39.56% | 62.40% | 56.46% | 48.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -82.48% | -57.58% | -21.46% | -27.55% | -29.57% |
| Cash from Investing | -83.50% | -57.99% | -19.73% | -27.23% | -29.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 24.00% | 12.16% | 0.28% | -26.62% | -72.97% |
| Issuance of Common Stock | -99.72% | -27.37% | 411.65% | 967.41% | 12,590.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -181.95% | -142.41% | 197.22% | 233.34% | 276.61% |
| Foreign Exchange rate Adjustments | -125.14% | 292.28% | 319.51% | 397.74% | 714.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -210.14% | -356.30% | -860.50% | -900.10% | -1,052.66% |